Participants will receive AB598 IV infusion in combination with zimberelimab once every 3 weeks, and FOLFOX (oxaliplatin, leucovorin, fluorouracil) every 2 weeks, for up to 2 years
Administered as specified in the treatment arm
Drug: Zimberelimab
Administered as specified in the treatment arm
Other Name: AB122
Drug: Fluorouracil
Administered as specified in the treatment arm
Drug: Leucovorin
Administered as specified in the treatment arm
Drug: Oxaliplatin
Administered as specified in the treatment arm
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
